Keith Ahamad1, Kanna Hayashi2, Paul Nguyen2, Sabina Dobrer2, Thomas Kerr3, Christian G Schütz4, Julio S Montaner3, Evan Wood5. 1. British Columbia Centre for Excellence in HIV/AIDS, St Paul's Hospital, Vancouver, BC, Canada; Department of Family Practice, University of British Columbia, Vancouver, BC, Canada. 2. British Columbia Centre for Excellence in HIV/AIDS, St Paul's Hospital, Vancouver, BC, Canada. 3. British Columbia Centre for Excellence in HIV/AIDS, St Paul's Hospital, Vancouver, BC, Canada; Department of Medicine, University of British Columbia, Vancouver, BC, Canada. 4. Department of Psychiatry, University of British Columbia, Vancouver, BC, Canada. 5. British Columbia Centre for Excellence in HIV/AIDS, St Paul's Hospital, Vancouver, BC, Canada; Department of Medicine, University of British Columbia, Vancouver, BC, Canada. Electronic address: uhri-ew@cfenet.ubc.ca.
Abstract
BACKGROUND: HIV infection in people who inject drugs (PWID) is an international public health concern. We aimed to assess the effect of methadone maintenance therapy on HIV incidence in PWID in Vancouver, BC, Canada, where methadone is widely available through family physicians' offices and dispensed by community pharmacies. METHODS: Data were derived from the Vancouver Injection Drug Users Study (VIDUS), a prospective cohort of PWID in Vancouver. Individuals were eligible to enrol in VIDUS if they had injected illicit drugs at least once in the previous month and lived in the Greater Vancouver region. Participants responded to an interviewer-administered questionnaire and provided blood samples at enrolment and follow-up visits every 6 months. We estimated time to HIV seroconversion with Kaplan-Meier methods and used Cox proportional hazards methods to assess associations between methadone use and time to seroconversion. FINDINGS: 1639 HIV-negative individuals were recruited between May 1, 1996, and May 31, 2013. Of these individuals, 138 had HIV seroconversion during a median of 75·5 months (IQR 33·4-115·3) of follow-up. In multivariate Cox regression analyses, methadone maintenance therapy remained independently associated with a reduced hazard of HIV infection after adjustment for sociodemographic characteristics and drug use patterns (adjusted relative hazard 0·64, 95% CI 0·41-0·98). INTERPRETATION: Methadone maintenance therapy for PWID made available through primary care physicians and community pharmacies can help to achieve public health goals such as reducing the spread of HIV. FUNDING: US National Institutes of Health, Canada Research Chair, Canadian Institutes of Health Research.
BACKGROUND:HIV infection in people who inject drugs (PWID) is an international public health concern. We aimed to assess the effect of methadone maintenance therapy on HIV incidence in PWID in Vancouver, BC, Canada, where methadone is widely available through family physicians' offices and dispensed by community pharmacies. METHODS: Data were derived from the Vancouver Injection Drug Users Study (VIDUS), a prospective cohort of PWID in Vancouver. Individuals were eligible to enrol in VIDUS if they had injected illicit drugs at least once in the previous month and lived in the Greater Vancouver region. Participants responded to an interviewer-administered questionnaire and provided blood samples at enrolment and follow-up visits every 6 months. We estimated time to HIV seroconversion with Kaplan-Meier methods and used Cox proportional hazards methods to assess associations between methadone use and time to seroconversion. FINDINGS: 1639 HIV-negative individuals were recruited between May 1, 1996, and May 31, 2013. Of these individuals, 138 had HIV seroconversion during a median of 75·5 months (IQR 33·4-115·3) of follow-up. In multivariate Cox regression analyses, methadone maintenance therapy remained independently associated with a reduced hazard of HIV infection after adjustment for sociodemographic characteristics and drug use patterns (adjusted relative hazard 0·64, 95% CI 0·41-0·98). INTERPRETATION:Methadone maintenance therapy for PWID made available through primary care physicians and community pharmacies can help to achieve public health goals such as reducing the spread of HIV. FUNDING: US National Institutes of Health, Canada Research Chair, Canadian Institutes of Health Research.
Authors: Grace E Macalino; David Vlahov; Stephanie Sanford-Colby; Sarju Patel; Keith Sabin; Christopher Salas; Josiah D Rich Journal: Am J Public Health Date: 2004-07 Impact factor: 9.308
Authors: Robert P Schwartz; Jerome H Jaffe; David A Highfield; Jason M Callaman; Kevin E O'Grady Journal: Drug Alcohol Depend Date: 2006-06-21 Impact factor: 4.492
Authors: Hans-Ulrich Wittchen; Sabine M Apelt; Michael Soyka; Markus Gastpar; Markus Backmund; Jörg Gölz; Michael R Kraus; Felix Tretter; Martin Schäfer; Jens Siegert; Norbert Scherbaum; Jürgen Rehm; Gerhard Bühringer Journal: Drug Alcohol Depend Date: 2008-03-11 Impact factor: 4.492
Authors: Hannah Fraser; Christinah Mukandavire; Natasha K Martin; Matthew Hickman; Myron S Cohen; William C Miller; Peter Vickerman Journal: Int J Epidemiol Date: 2017-04-01 Impact factor: 7.196
Authors: M Eugenia Socías; Evan Wood; Will Small; Huiru Dong; Jean Shoveller; Thomas Kerr; Julio Montaner; M-J Milloy Journal: Drug Alcohol Depend Date: 2016-09-20 Impact factor: 4.492
Authors: N A Mohd Salleh; N Fairbairn; S Nolan; R Barrios; J Shoveller; L Richardson; M-J Milloy Journal: HIV Med Date: 2019-07-29 Impact factor: 3.180
Authors: Amy Prangnell; Kate Shannon; Ekaterina Nosova; Kora DeBeck; M-J Milloy; Thomas Kerr; Kanna Hayashi Journal: J Public Health Policy Date: 2018-02 Impact factor: 2.222